Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
Pain Med ; 11(6): 912-9, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20624243

ABSTRACT

OBJECTIVE: To evaluate the efficacy of a novel variant of electroencephalograph biofeedback, the Low Energy Neurofeedback System (LENS), that utilizes minute pulses of electromagnetic stimulation to change brainwave activity for the amelioration of fibromyalgia (FM) symptoms. DESIGN: Randomized, double-blind, placebo-controlled clinical trial. SETTING: Tertiary referral academic medical center, outpatient. PATIENTS: Thirty-four patients diagnosed with FM according to 1990 American College of Rheumatology classification criteria. INTERVENTIONS: Active or sham LENS, depending on randomization, for 22 treatment sessions. OUTCOME MEASURES: Primary outcome measure was the Fibromyalgia Impact Questionnaire total score. Secondary outcome measures included number of tender points (TPs) and pressure required to elicit TPs on physical examination, quantitative sensory testing heat pain threshold, and self-reported cognitive dysfunction, fatigue, sleep problems, global psychological distress, and depression obtained at baseline, immediate post-treatment, and 3- and 6-month follow-up. RESULTS: Participants who received the active or sham interventions improved (Ps < 0.05) on the primary and a variety of secondary outcome measures, without statistically significant between group differences in evidence at post-treatment or 3- or 6-month follow-up. Individual session self-reported ratings of specific symptoms (cognitive dysfunction, fatigue, pain, and sleep, and overall activity level) over the course of the 22 intervention sessions indicated significant linear trends for improvement for the active intervention condition only (Ps < 0.05). CONCLUSION: LENS cannot be recommended as a single modality treatment for FM. However, further study is warranted to investigate the potential of LENS to interact synergistically with other pharmacologic and nonpharmacologic therapies for improving symptoms in FM.


Subject(s)
Biofeedback, Psychology/methods , Fibromyalgia/therapy , Pain Management , Adult , Double-Blind Method , Female , Fibromyalgia/complications , Humans , Male , Middle Aged , Outpatients , Pain/etiology , Pain Measurement , Placebos/therapeutic use , Surveys and Questionnaires , Treatment Outcome
2.
Clin Neuropsychol ; 24(2): 220-34, 2010 Feb.
Article in English | MEDLINE | ID: mdl-19859855

ABSTRACT

We compared MMPI-2 profiles of Gulf War veterans with fibromyalgia (FM) to epileptic seizure (ES) patients, psychogenic non-epileptic seizure (PNES) patients, and Gulf War veteran healthy controls. Both PNES and FM are medically unexplained conditions. In previous MMPI-2 research PNES patients were shown to have significantly higher Hs and Hy clinical scales than ES patients. In the present research the FM group had significantly higher Hs and Hy scale scores than both the ES group and the healthy control group. There was no significant difference between the FM and PNES Hs scale scores; however, the FM Hy scale score was significantly lower than the PNES Hy scale score. Present findings indicate a high level of psychological distress in the FM group.


Subject(s)
Depressive Disorder/diagnosis , Depressive Disorder/epidemiology , Epilepsy/epidemiology , Epilepsy/psychology , Fibromyalgia/epidemiology , Fibromyalgia/psychology , MMPI , Personality Disorders/diagnosis , Personality Disorders/epidemiology , Psychophysiologic Disorders/diagnosis , Psychophysiologic Disorders/epidemiology , Seizures/epidemiology , Seizures/psychology , Adult , Depressive Disorder/psychology , Female , Gulf War , Humans , Male , Personality Disorders/psychology , Psychophysiologic Disorders/psychology , Severity of Illness Index , Veterans/psychology , Veterans/statistics & numerical data
3.
Arthritis Rheum ; 58(9): 2882-91, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18759308

ABSTRACT

OBJECTIVE: To assess the efficacy of pegloticase in achieving and maintaining plasma urate levels of <6 mg/dl in gout patients in whom other treatments have failed, and to assess the pharmacokinetics and safety of pegloticase. METHODS: Forty-one patients were randomized to undergo 12-14 weeks of treatment with pegloticase at 1 of 4 dosage levels: 4 mg every 2 weeks, 8 mg every 2 weeks, 8 mg every 4 weeks, or 12 mg every 4 weeks. Plasma uricase activity, plasma urate, and antipegloticase antibodies were measured, pharmacokinetic parameters were assessed, and adverse events were recorded. RESULTS: The mean plasma urate level was reduced to

Subject(s)
Gout/drug therapy , Polyethylene Glycols/administration & dosage , Urate Oxidase/administration & dosage , Uric Acid/blood , Adult , Aged , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Humans , Intention to Treat Analysis , Male , Middle Aged , Patient Selection , Polyethylene Glycols/adverse effects , Polyethylene Glycols/pharmacokinetics , Treatment Outcome , Urate Oxidase/adverse effects , Urate Oxidase/pharmacokinetics
4.
Mil Med ; 171(9): 917-23, 2006 Sep.
Article in English | MEDLINE | ID: mdl-17036619

ABSTRACT

Although the health benefits of exercise for individuals with Persian Gulf War veterans illnesses (GWVI) are documented, many of these individuals do not exercise regularly enough to obtain benefits. The purpose of this study was to investigate factors predicting exercise compliance among individuals with GWVI in a multicenter, randomized, clinical trial. Participants were 1,092 veterans who reported at least two of the following cardinal symptoms of GWVI: (1) fatigue, (2) musculoskeletal pain, and (3) cognitive problems. Participants received exercise alone or exercise and cognitive-behavioral therapy. The overall level of compliance was relatively low during the exercise treatment phase (46.2%) and decreased by one-half during the follow-up period (23.0%). Predictors of compliance during treatment included less pain and greater age, motivation, and body mass index. Predictors of compliance during the follow-up period included less pain and greater age. The results highlight factors that affect adoption and maintenance of physical activity in a population with GWVI.


Subject(s)
Exercise Therapy , Military Medicine , Patient Compliance/psychology , Persian Gulf Syndrome/psychology , Veterans/psychology , Adult , Aged , Cognition Disorders/prevention & control , Fatigue/prevention & control , Female , Gulf War , Hospitals, Military , Hospitals, Veterans , Humans , Male , Middle Aged , Odds Ratio , Persian Gulf Syndrome/physiopathology , Persian Gulf Syndrome/rehabilitation , Prognosis , Sickness Impact Profile , Surveys and Questionnaires , United States , Veterans/statistics & numerical data
5.
Curr Pain Headache Rep ; 10(5): 327-32, 2006 Oct.
Article in English | MEDLINE | ID: mdl-16945247

ABSTRACT

Fibromyalgia is a common disorder of diffuse musculoskeletal pain. Several rheumatic diseases can mimic fibromyalgia, and a clinician would not want to miss these diagnoses because of their potential long-term sequelae, such as progressive joint damage or life- or organ-threatening disease if they remain untreated. This paper discusses the typical clinical presentations of selected rheumatic diseases (systemic lupus erythematosus, rheumatoid arthritis, ankylosing spondylitis, polymyalgia rheumatica, and osteoarthritis) then highlights the key features in history, laboratory testing, and radiographic imaging that aid the clinician in differentiating between fibromyalgia and these rheumatic diseases.


Subject(s)
Fibromyalgia/diagnosis , Rheumatic Diseases/diagnosis , Animals , Diagnosis, Differential , Humans
6.
J Rheumatol ; 33(9): 1805-12, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16960941

ABSTRACT

OBJECTIVE: To evaluate the efficacy and safety of celecoxib in patients with ankylosing spondylitis (AS). METHODS: This was a 12-week randomized, double-blind, placebo-controlled study with 4 treatment arms: celecoxib 200 mg qd, celecoxib 400 mg qd, naproxen 500 mg bid, and placebo. Patients (age 18-75 yrs) requiring daily treatment with nonselective nonsteroidal antiinflammatory drugs, and with a pain intensity on visual analog scale (VAS) > or = 50 mm worsening by 30% compared with a preinclusion visit (14 days prior) were studied. Primary endpoints were least-squares mean changes from baseline in pain intensity, disease activity (patient global assessment VAS), and functional impairment [Bath Ankylosing Spondylitis Functional Index (BASFI)]. Adverse events were monitored throughout the study. RESULTS: Of 611 randomized patients, 137 were allocated to celecoxib 200 mg, 161 to celecoxib 400 mg, 157 to naproxen, and 156 to placebo. Improvements in least-squares mean pain intensity, disease activity, and BASFI scores were significantly greater in the celecoxib 200 mg, celecoxib 400 mg, and naproxen groups than in the placebo group (p < or = 0.001) at Week 12 and the interim timepoints, Weeks 1, 3, and 6. Celecoxib 400 mg was as effective as naproxen; however, naproxen was more effective than celecoxib 200 mg. Celecoxib was well tolerated, with an adverse event profile similar to placebo. However, 3 naproxen-treated patients experienced serious treatment-related gastrointestinal (GI) adverse events (one severe gastric ulcer, one moderate GI hemorrhage, one severe GI hemorrhage). CONCLUSION: In this 12-week study, celecoxib 200 mg qd and 400 mg qd were efficacious and well tolerated in treating signs and symptoms of AS.


Subject(s)
Pyrazoles/administration & dosage , Spondylitis, Ankylosing/diagnosis , Spondylitis, Ankylosing/drug therapy , Sulfonamides/administration & dosage , Adult , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Celecoxib , Dose-Response Relationship, Drug , Double-Blind Method , Female , Humans , Male , Placebo Effect , Pyrazoles/adverse effects , Sulfonamides/adverse effects , Treatment Outcome
7.
Curr Pain Headache Rep ; 9(5): 301-6, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16157056

ABSTRACT

Fibromyalgia is a syndrome of widespread pain, nonrestorative sleep, disturbed mood, and fatigue. Optimal treatment involves a multidisciplinary approach with a team of health care providers using pharmacologic and nonpharmacologic treatment. Because of the heterogeneity of the illness, management should be individualized for the patient. Pharmacologic treatment should address issues of pain control, sleep disturbance, fatigue, and any underlying coexisting mood disorder. Nonpharmacologic treatment should include patient education, a regular exercise and stretching program, and cognitive behavioral therapy. All of these are essential to improving functional capacity and quality of life. This review provides general guidelines in initiating a successful pharmacologic treatment program for patients with fibromyalgia.


Subject(s)
Fibromyalgia/drug therapy , Analgesics/therapeutic use , Fatigue/drug therapy , Fatigue/etiology , Fibromyalgia/complications , Fibromyalgia/psychology , Humans , Mood Disorders/drug therapy , Mood Disorders/etiology , Pain/drug therapy , Pain/etiology , Sleep Wake Disorders/drug therapy , Sleep Wake Disorders/etiology
8.
Otolaryngol Clin North Am ; 36(4): 685-705, 2003 Aug.
Article in English | MEDLINE | ID: mdl-14567060

ABSTRACT

Wegener's granulomatosis is an idiopathic, granulomatous disease with the potential for multiple head and neck manifestations. The otolarygologist is an essential part of the multidisciplinary team involved in establishing the diagnosis and providing ongoing care for patients with Wegener's granulomatosis. Diagnostic difficulties abound in Wegener's granulomatosis, making repeat biopsies and the use of ANCA imperative. Medical therapy consisting of corticosteroids and immunosuppressive agents is the mainstay of treatment in Wegener's granulomatosis, whereas surgery is reserved for selected head and neck manifestations. With appropriate medical and surgical treatment, many patients living with Wegener's granulomatosis can enjoy a good quality of life.


Subject(s)
Granulomatosis with Polyangiitis/complications , Otorhinolaryngologic Diseases/etiology , Adrenal Cortex Hormones/therapeutic use , Antibodies, Antineutrophil Cytoplasmic/analysis , Biopsy , Diagnosis, Differential , Eye Diseases/etiology , Granulomatosis with Polyangiitis/diagnosis , Granulomatosis with Polyangiitis/therapy , Hearing Disorders/etiology , Humans , Otorhinolaryngologic Diseases/diagnosis
9.
Curr Pain Headache Rep ; 7(5): 342-7, 2003 Oct.
Article in English | MEDLINE | ID: mdl-12946286

ABSTRACT

Fibromyalgia and chronic hepatitis C infection share many clinical features including prominent somatic complaints such as musculoskeletal pain and fatigue. There is a growing body of evidence supporting a link between cytokines and somatic complaints. This review discusses alterations of cytokines in fibromyalgia, including increased serum levels of interleukin (IL)-2, IL-2 receptor, IL-8, IL-1 receptor antagonist; increased IL-1 and IL-6 produced by stimulated peripheral blood mononuclear cell in patients with FM for longer than 2 years; increased gp130, which is a neutrophil cytokine transducing protein; increased soluble IL-6 receptor and soluble IL-1 receptor antagonist only in patients with fibromyalgia who are depressed; and IL-1 beta, IL-6, and TNF-a by reverse transcriptase-polymerase chain reaction in skin biopsies of some patients with fibromyalgia. In addition, this review describes the mechanism by which alterations in cytokines in fibromyalgia and chronic hepatitis C infection can produce hyperalgesia and other neurally mediated symptoms through the presence of cytokine receptors on glial cells and opiate receptors on lymphocytes and the influence of cytokines on the hypothalamus-pituitary-adrenal axis such as IL-1, IL-6, and TNF-a activating and IL-2 and IFN-a down-regulating the HPA axis, respectively. The association between chronic hepatitis C infection and fibromyalgia is discussed, including a description of key cytokine changes in chronic hepatitis C infection. Future studies are encouraged to further characterize these immunologic alterations with potential pathophysiologic and therapeutic implications.


Subject(s)
Cytokines/immunology , Fibromyalgia/immunology , Hepatitis C, Chronic/immunology , Antigens, CD/immunology , Biopsy , Fibromyalgia/diagnosis , Hepatitis C, Chronic/diagnosis , Humans , Interleukin-1/immunology , Interleukin-2/immunology , Interleukin-6/immunology , Interleukin-8/immunology , Reverse Transcriptase Polymerase Chain Reaction , Skin/pathology , Tumor Necrosis Factor-alpha/immunology
10.
JAMA ; 289(11): 1396-404, 2003 Mar 19.
Article in English | MEDLINE | ID: mdl-12636462

ABSTRACT

CONTEXT: Gulf War veterans' illnesses (GWVI), multisymptom illnesses characterized by persistent pain, fatigue, and cognitive symptoms, have been reported by many Gulf War veterans. There are currently no effective therapies available to treat GWVI. OBJECTIVE: To compare the effectiveness of cognitive behavioral therapy (CBT), exercise, and the combination of both for improving physical functioning and reducing the symptoms of GWVI. DESIGN, SETTING, AND PATIENTS: Randomized controlled 2 x 2 factorial trial conducted from April 1999 to September 2001 among 1092 Gulf War veterans who reported at least 2 of 3 symptom types (fatigue, pain, and cognitive) for more than 6 months and at the time of screening. Treatment assignment was unmasked except for a masked assessor of study outcomes at each clinical site (18 Department of Veterans Affairs [VA] and 2 Department of Defense [DOD] medical centers). INTERVENTIONS: Veterans were randomly assigned to receive usual care (n = 271), consisting of any and all care received from inside or outside the VA or DOD health care systems; CBT plus usual care (n = 286); exercise plus usual care (n = 269); or CBT plus exercise plus usual care (n = 266). Exercise sessions were 60 minutes and CBT sessions were 60 to 90 minutes; both met weekly for 12 weeks. MAIN OUTCOME MEASURES: The primary end point was a 7-point or greater increase (improvement) on the Physical Component Summary scale of the Veterans Short Form 36-Item Health Survey at 12 months. Secondary outcomes were standardized measures of pain, fatigue, cognitive symptoms, distress, and mental health functioning. Participants were evaluated at baseline and at 3, 6, and 12 months. RESULTS: The percentage of veterans with improvement in physical function at 1 year was 11.5% for usual care, 11.7% for exercise alone, 18.4% for CBT plus exercise, and 18.5% for CBT alone. The adjusted odds ratios (OR) for improvement in exercise, CBT, and exercise plus CBT vs usual care were 1.07 (95% confidence interval [CI], 0.63-1.82), 1.72 (95% CI, 0.91-3.23), and 1.84 (95% CI, 0.95-3.55), respectively. The OR for the overall (marginal) effect of receiving CBT (n = 552) vs no CBT (n = 535) was 1.71 (95% CI, 1.15-2.53) and for exercise (n = 531) vs no exercise (n = 556) was 1.07 (95% CI, 0.76-1.50). For secondary outcomes, exercise alone or in combination with CBT significantly improved fatigue, distress, cognitive symptoms, and mental health functioning, while CBT alone significantly improved cognitive symptoms and mental health functioning. Neither treatment had a significant impact on pain. CONCLUSION: Our results suggest that CBT and/or exercise can provide modest relief for some of the symptoms of chronic multisymptom illnesses such as GWVI.


Subject(s)
Cognitive Behavioral Therapy , Exercise , Military Personnel , Persian Gulf Syndrome/therapy , Adult , Cognition Disorders , Fatigue , Female , Humans , Male , Pain , Treatment Outcome
11.
J Clin Rheumatol ; 9(1): 51-3, 2003 Feb.
Article in English | MEDLINE | ID: mdl-17041424

ABSTRACT

Dermatomyositis is a disease frequently treated by rheumatologists and dermatologists due to prominent systemic features of inflammatory myositis, less common arthritis, and rare systemic vasculitis, in addition to the characteristic cutaneous manifestations of Gottron's papules over extensor surfaces, and a heliotrope rash over the eyelids. Patients with amyopathic dermatomyositis, a subset of dermatomyositis, display skin disease but no apparent muscle disease. This report describes an adult patient with the typical dermatomyositis rash with no weakness, normal muscle enzymes, and the unique finding of fasciitis without myositis on muscle biopsy, which correlated with a Magnetic Resonance Imaging (MRI) finding of a peripheral halo of intense signal around muscles on T2-weighted and fat suppression sequences. Although MRI finding of presumed fasciitis has been reported in juvenile-onset dermatomyositis, this is the first report of MRI evidence of fasciitis with pathological correlation in adult-onset dermatomyositis. We suggest that if MRI scans are ordered, as part of the work-up of dermatomyositis, a peripheral halo of increased signal should specifically be looked for, which could be interpreted as fasciitis based on this case report.

12.
Curr Pain Headache Rep ; 6(4): 284-8, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12095463

ABSTRACT

Fibromyalgia is a chronic pain syndrome of unknown etiology characterized by diffuse pain and tender points, which have been present for more than 3 months. Many patients with systemic illnesses can have diffuse pain similar to that found in fibromyalgia, including rheumatic diseases such as polymyalgia rheumatica, rheumatoid arthritis, idiopathic inflammatory myopathy, systemic lupus erythematosus, and joint hypermobility. Osteomalacia and thyroid disease are also in the differential diagnosis of diffuse pain and are imminently treatable. In addition, there has been interest throughout the past 10 years in infectious diseases including hepatitis C, Lyme disease, coxsackie B, HIV, and parvovirus infection, which may cause or trigger fibromyalgia. This paper provides a framework to use when identifying these diseases as part of the evaluation of a patient with chronic widespread musculoskeletal pain.


Subject(s)
Fibromyalgia/diagnosis , Rheumatic Diseases/diagnosis , Diagnosis, Differential , Fibromyalgia/etiology , Humans , Medical History Taking , Risk Factors
13.
Rheum Dis Clin North Am ; 28(2): 261-90, 2002 May.
Article in English | MEDLINE | ID: mdl-12122917

ABSTRACT

Despite disappointing results when subjected to randomized clinical trials, pharmacologic agents remain an important component of FM management. Addressing the main symptoms of pain, disturbed sleep, mood disturbances, fatigue, and associated conditions is essential to improve patient functioning and enhanced quality of life. However, much work remains to design clinical trials which address the complexity of FM, while satisfying evidence based medicine paradigms.


Subject(s)
Fibromyalgia/drug therapy , Fatigue/drug therapy , Fatigue/etiology , Fibromyalgia/complications , Humans , Mood Disorders/drug therapy , Mood Disorders/etiology , Sleep Wake Disorders/drug therapy , Sleep Wake Disorders/etiology
14.
Arch Environ Health ; 57(4): 340-8, 2002.
Article in English | MEDLINE | ID: mdl-12530602

ABSTRACT

Fatigue has been associated with illness in veterans of the Gulf War; however, few studies have confirmed self-reported fatigue by using clinical evaluation, and symptomatic veterans have not been evaluated with established criteria for Chronic Fatigue Syndrome (CFS). The authors describe the frequency and clinical characteristics of CFS in a sample of veterans residing in the northwestern United States. The sample was selected randomly from U.S. Department of Defense databases of troops deployed to southwest Asia during the Gulf War. The selected individuals were invited to participate in a clinical case-control study of unexplained illness. Of 799 survey respondents eligible for clinical evaluation, 178 had fatigue symptoms. Of the 130 veterans who were evaluated clinically, 103 had unexplained fatigue, and 44 veterans met the 1994 U.S. Centers for Disease Control criteria for CFS. In this population, the authors estimated a minimum prevalence of any unexplained fatigue to be 5.1%, and of CFS to be 2.2%. The estimated prevalence was greater among females than among males. Cases were similar to healthy controls, as determined by laboratory tests and physical findings. In comparison to several clinical studies of CFS patients, the authors of this study found a lower proportion of veterans who reported a sudden onset of symptoms (19%) vs. a gradual onset (50%). Although it has previously been suggested that veterans of the Gulf War suffer from higher rates of chronic fatigue than the general population, the study results described herein--on the basis of clinical examination of a population-based sample of veterans-actually indicate that an increased rate may indeed exist. Gulf War veterans with unexplained fatigue should be encouraged to seek treatment so that the impact of these symptoms on overall quality of life can be reduced.


Subject(s)
Fatigue Syndrome, Chronic/etiology , Persian Gulf Syndrome/etiology , Veterans , Adult , Case-Control Studies , Fatigue Syndrome, Chronic/epidemiology , Fatigue Syndrome, Chronic/pathology , Female , Humans , Male , Persian Gulf Syndrome/epidemiology , Persian Gulf Syndrome/pathology , Prevalence , Severity of Illness Index , Sex Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...